ArrowArtboardCreated with Sketch.Title ChevronCrossEye IconFacebook IconIcon FacebookGoogle Plus IconLayer 1InstagramCreated with Sketch.Linkedin IconIcon LinkedinShapeCreated with Sketch.Icon Mail ContactPath LayerIcon MailMenu BurgerIcon Opinion QuotePositive ArrowIcon PrintRSS IconIcon SearchSite TitleTitle ChevronTwitter IconIcon TwitterYoutube Icon
Health Technology

Lupin Ltd.

  • 854.70 INR
  • -24.65
  • -2.80%
  • India
    Aug 17, 2018
  • Ticker
  • Prev. close
  • Market cap (INR)
  • Market cap (USD)
  • Shares

Company Background

Lupin is a major generic drugmaker that conducts business in more than 100 countries. Among India's five biggest pharmaceuticals, it has about 10 production bases in India and exports generic drugs to other countries.

It was founded in 1968 by Desh Bandhu Gupta, a researcher at a science university. Since the early 2000s, it has been actively buying companies in South Africa, Mexico, even Japan.

It got a head start on its Indian competitors by building a supply network in Japan. It did so in 2007 by acquiring Kyowa Pharmaceutical Industry, an Osaka-based medium-size generic drugmaker. In 2014, it set up a venture with Yoshindo, a generic drug company based in Japan's Toyama Prefecture, to jointly develop generic biomedicines.

Zyma Laboratories, an affiliate company run by Desh Bandhu Gupta and other executives, is Lupin's top shareholder; the founding family still owns some shares in Lupin.

Business Summary

Lupin Ltd. engages in the manufacture of pharmaceutical products. Its offers branded and generic formulations, biotechnology products, and active pharmaceutical ingredients. The firm caters to the cardiovascular, diabetology, asthama, pediatrics, central nervous system, gastro-intestinal, anti-infectives, nonsteroidal anti-inflammatory drug therapy, anti-tuberculosis, and cephalosporins industry segments. It operates through the following geographical segments: India, USA, Japan, and Others. The company was founded by Desh Bandhu Gupta in 1968 and is headquartered in Mumbai, India.

Financial Highlights

Mar 2018 INRUSD
Gross Profit60,769.20M942.65M
Operating income18,628.40M288.96M
Income before tax5,432.90M84.27M
Net income2,512.60M38.97M
Diluted EPS5.540.08
Dividends Per Share50.07
Total Assets263,053.80M4,033.22M
Total liabilities126,882.40M1,945.40M
Total equity135,761.40M2,081.53M
Operating cash flow15,901M246.65M
Currency in INRCurrency in USD

Historical Data

 Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018
Revenue 110,859.10M 125,988.70M 137,818.50M 170,090.50M 155,509.10M
Gross Profit 44,273M 59,588.70M 67,159.10M 83,802.20M 60,769.20M
Operating income 26,508.20M 31,579.50M 32,615.50M 33,543.30M 18,628.40M
Income before tax 28,316.50M 34,148.30M 33,239.40M 35,348.90M 5,432.90M
Net income 18,363.70M 24,032.40M 22,607.40M 25,574.60M 2,512.60M
EBITDA 29,117.90M 35,926.50M 37,486.80M 42,665.60M 29,487.10M
Diluted EPS 40.79 53.20 49.93 56.46 5.54
Dividends Per Share 6 7.50 7.50 7.50 5
Total Assets 102,753.50M 132,271.80M 226,248.60M 266,072.80M 263,053.80M
Total liabilities 32,768.40M 43,290.20M 114,294.10M 130,751.90M 126,882.40M
Total equity 69,306.50M 88,731.40M 111,624.50M 134,966.50M 135,761.40M
Operating cash flow 19,906.70M 27,947M -4,269.70M 40,092.80M 15,901M
 Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018
Revenue 1,834.37M 2,060.54M 2,105.03M 2,536.50M 2,412.26M
Gross Profit 732.58M 974.57M 1,025.78M 1,249.71M 942.65M
Operating income 438.62M 516.48M 498.16M 500.22M 288.96M
Income before tax 468.55M 558.49M 507.69M 527.14M 84.27M
Net income 303.86M 393.04M 345.30M 381.38M 38.97M
EBITDA 481.81M 587.57M 572.57M 636.25M 457.40M
Diluted EPS 0.67 0.87 0.76 0.84 0.08
Dividends Per Share 0.09 0.12 0.11 0.11 0.07
Total Assets 1,720.51M 2,113.60M 3,416.49M 4,097.52M 4,033.22M
Total liabilities 548.67M 691.74M 1,725.91M 2,013.58M 1,945.40M
Total equity 1,160.47M 1,417.85M 1,685.59M 2,078.48M 2,081.53M
Operating cash flow 329.39M 457.07M -65.21M 597.89M 246.65M

Valuation Measures

Mar 2018
Operating margin11.97%
Profit margin1.61%

Key executives

  • Managing Director & Executive Director: Nilesh Deshbandhu Gupta
  • Chief Executive Officer & Executive Director: Vinita D. Gupta
  • Chief Financial Officer & Executive Director: Ramesh Swaminathan
  • President-Technical Operations: Alok Ghosh
  • President-Asia Pacific & Japan Region: Fabrice Egros


  • Lupin Investments Pvt Ltd. (45.4%)
  • Life Insurance Corp. of India (2.6%)
  • Genesis Investment Management LLP (2.3%)
  • ICICI Prudential Asset Management Co. Ltd. (1.7%)
  • The Vanguard Group, Inc. (1.6%)
  • BlackRock Fund Advisors (1.3%)
  • Norges Bank Investment Management (1.3%)
  • Comgest SA (1.2%)
  • Franklin Templeton Asset Management (India) Pvt Ltd. (1.2%)

Contact Details

  • Website:
  • Address: B/4 Laxmi Towers, Bandra Kurla Complex, Mumbai, 400051, India
  • Phone: +91.22.66402222

Related Companies

  • Lupin Atlantis Holdings SA
  • Lupin Farmaceutica Do Brasil Ltda.
  • Lupin Pharmaceuticals Ltd/Brazil/
  • Lupin Employees Benefit Trust
  • Nanomi BV
  • Lupin Healthcare Ltd.
  • GAVIS Pharmaceuticals LLC
  • Lupin Chemical (Thailand) Ltd.
  • Lupin Holdings B.V., Netherlands
  • Polynova Industries Ltd.
  • Lupin Laboratories Ltd.
  • Laboratorios Grin SA de CV
  • Lupin Pharmaceuticals, Inc.
  • Multicare Pharmaceuticals Philippines, Inc.
  • Pharma Dynamics Pty Ltd.
  • Hormosan Pharma GmbH
  • Kyowa Pharmaceutical Industry Co., Ltd.
  • Rubamin Laboratories Ltd.
  • Lupin Chemicals Ltd.
  • Temmler Pharma GmbH & Co. KG
  • Lupin Herbal Pvt. Ltd.


  • Novartis AG
  • Mylan N.V.
  • Teva Pharmaceutical Industries Limited
  • Aurobindo Pharma Ltd
  • Dr. Reddy's Laboratories Ltd.
  • GlaxoSmithKline Pharmaceuticals Limited
  • Biocon Limited
  • Unichem Laboratories Limited
  • Amneal Pharmaceuticals, Inc. Class A
  • Gemphire Therapeutics Inc.
  • Agile Therapeutics, Inc.
  • Omeros Corporation
  • Midatech Pharma Plc
  • Momenta Pharmaceuticals, Inc.
Last Updated on 17 Aug, 2018

You have {{numberReadArticles}} FREE ARTICLE{{numberReadArticles-plural}} left this month

Subscribe to get unlimited access to all articles.

Get unlimited access
NAR site on phone, device, tablet

You have {{numberReadArticles}} FREE ARTICLE{{numberReadArticles-plural}} left this month

Subscribe to get unlimited access to all articles.

3 months for $9

Get unlimited access
NAR site on phone, device, tablet

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media